PHILOGEN SPA - Italy 

Ranking results:

Past rankings:

2012
Criterium:Position:
Overall Score:900-1000
Total Project Funding per Partner:700-800
Total Number of Projects:68
Total Project Funding:500-600
Networking Rank (Reputation):800-900
Networking Rank (Reputation):800-900
Partner Constancy:46
Project Leadership Index:75
Diversity Index:60
2011
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
Total Project Funding:> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:> 1000

Ranking timeline:

Project Participation Performance(2011-01-01 - 2024-12-31 ):

Total Project Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:

Leadership:

Total number of projects: 5
As coordinator: 0
As participant: 5
Sole participant: 0
Coordinator / Participant Ratio: 0*

*Ratio includes only projects with > 2 partners

Summary:

Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2017 0 5.994.176 726.250 1
2013 0 5.931.151 625.900 1
2012 0 20.680.031 2.970.938 3
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:

Institution:Projects [No]:
EBERHARD KARLS UNIVERSITAET TUEBINGEN3
UNIVERSITY COLLEGE LONDON3
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS2
KATHOLIEKE UNIVERSITEIT LEUVEN2
PHILOCHEM2
STICHTING HET NEDERLANDS KANKER INSTITUUTANTONI VAN LEEUWENHOEK ZIEKENHUIS2
STICHTING KATHOLIEKE UNIVERSITEIT2
UNIVERSITAET ZUERICH2
ACADEMISCH ZIEKENHUIS MAASTRICHT1
ACQUIFER1
AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS1
CELLECTICS THERAPEUTICS SAS1
CENTRE OSCAR LAMBRET1
CENTRUM ONKOLOGII INSTYTUT IM MARII SKLODOWSKIECURIE1
CHARITE UNIVERSITAETSMEDIZIN BERLIN1
CLINIQUES UNIVERSITAIRES SAINTLUC1
COMPREHENSIVE BIOMARKER CENTER1
DANMARKS TEKNISKE UNIVERSITET1
EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH1
EUROPEAN CANCER PATIENT COALITION1
FUNDACIO PRIVADA CLINIC PER A LA RECERCA BIOMEDICA1
GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG GAB O1
GENOMATIX SOFTWARE1
HACETTEPE UNIVERSITESI1
HEALTH INNOVATION VENTURES BV1
IMMATICS BIOTECHNOLOGIES1
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE1
ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI1
KARLSRUHER INSTITUT FUER TECHNOLOGIE1
KLINIKUM DER FRIEDRICH SCHILLER UNIVERSITAET JENA1
LEIBNIZ INSTITUT FUR NATURSTOFF FORSCHUNG UND INFEKTIONSBIOLOGIE EV HANS KNOLL INSTITUTE1
LUDWIG MAXIMILIANS UNIVERSITAET MUENCHEN1
MEDIZINISCHE UNIVERSITAT GRAZ1
MEDIZINISCHE UNIVERSITAT GRAZ MEDUNI GRAZ1
METABOMETRIX LIMITED1
MOSAIQUES DIAGNOSTICS1
MULTIPLICOM NV1
OULUN YLIOPISTO1
PT THERAGNOSTIC BV1
REGION HOVEDSTADEN1
STICHTING VUVUMC1
TECHNISCHE UNIVERSITAET DRESDEN1
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD1
THE REGENTS OF THE UNIVERSITY OF MICHIGAN1
THE UNIVERSITY OF MANCHESTER1
THE UNIVERSITY OF NOTTINGHAM1
UNIVERSITA CATTOLICA DEL SACRO CUORE1
UNIVERSITAETSKLINIKUM ESSEN1
UNIVERSITAETSKLINIKUM HEIDELBERG1
UNIVERSITAIR MEDISCH CENTRUM UTRECHT1
UNIVERSITAIR ZIEKENHUIS GENT1
UNIVERSITEIT MAASTRICHT1
UNIVERSITY OF BRISTOL1
UNIVERSITY OF NEWCASTLE UPON TYNE1

Constancy:

Total number of partners: 64
Partner loyalty:
Frequent Partner: (> 2 projects): 6
Rare Partner: 58
Frequent / Rare Partner Ratio: 0.1

Project overview:

Start dateProjectacronymrolefundingpartners
2017-01-01Clinical proof of concept through a randomised phase II study: a combination of immunotherapy and stereotactic ablative radiotherapy as a curative treatment for limited metastatic lung cancer IMMUNOSABRparticipant5.994.17617
2013-12-01Advanced T-cell Engineered for Cancer Therapy ATECTparticipant5.931.1515
2012-11-01Profiling Responders In Antibody Therapies PRIATparticipant2.967.4858
2012-10-01European Consortium for High-Throughput Research in Rare Kidney Diseases EURENOMICSparticipant11.994.56728
2012-01-01IMmune MOdulating strategies for treatment of MErkel cell Carcinoma IMMOMECparticipant5.717.97911

Alias institution names:

  • PHILOGEN